{"id":18716,"date":"2022-08-30T17:11:15","date_gmt":"2022-08-30T11:41:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18716"},"modified":"2022-10-13T10:34:56","modified_gmt":"2022-10-13T05:04:56","slug":"pharma-news-for-aktis-alcon-takeda","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda","title":{"rendered":"Aktis\u2019s Novel Targeted Alpha Radiopharmaceuticals; Koye Partners with Sonde Health; Novartis to Spin Off Sandoz Business; Alcon to Buy Aerie Pharma; Fast Track Designation to Merck\u2019s MK-2060; FDA Approves Ibrutinib for Chronic GvHD; French Authorities Clears BrainVectis\u2019s Clinical Trial; Takeda\u2019s Dengue Vaccine TAK-003 Gets Approval in Indonesia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d270ac46aeb\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d270ac46aeb\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#Aktis_Oncology_Raises_USD_84_Million_To_Advance_Novel_Targeted_Alpha_Radiopharmaceuticals\" >Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#Koye_Pharma_Partners_with_Sonde_Health_to_Develop_its_Vocal_Biomarker_Technology_for_COPD\" >Koye Pharma Partners with Sonde Health to Develop its Vocal Biomarker Technology for COPD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#Novartis_Announces_Intention_to_Separate_Sandoz_to_Create_a_Standalone_Company\" >Novartis Announces Intention to Separate Sandoz to Create a Standalone Company<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#Alcon_to_Buy_Aerie_Pharma_for_About_USD_753_Million\" >Alcon to Buy Aerie Pharma for About USD 753 Million<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#FDA_Approves_Ibrutinib_for_Pediatric_Patients_With_Chronic_GVHD\" >FDA Approves Ibrutinib for Pediatric Patients With Chronic GVHD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#FDA_Grants_Fast_Track_Designation_to_Mercks_MK-2060_for_ESRD\" >FDA Grants Fast Track Designation to Merck\u2019s MK-2060 for ESRD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#France_Regulator_Gives_The_Green_Light_to_Bayers_Asklepios_BioPharma_to_Start_Dosing_Patients_with_its_Gene_Therapy_Candidate\" >France Regulator Gives The Green Light to Bayer\u2019s Asklepios BioPharma to Start Dosing Patients with its Gene Therapy Candidate<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\/#Takeda_Secures_its_First_Regulatory_Approval_in_Indonesia_for_its_Dengue_Fever_Vaccine_TAK-003\" >Takeda Secures its First Regulatory Approval in Indonesia for its Dengue Fever Vaccine TAK-003<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-aktis-oncology-raises-usd-84-million-to-advance-novel-targeted-alpha-radiopharmaceuticals\"><span class=\"ez-toc-section\" id=\"Aktis_Oncology_Raises_USD_84_Million_To_Advance_Novel_Targeted_Alpha_Radiopharmaceuticals\"><\/span><strong>Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Aktis Oncology <\/strong>has raised an additional <strong>USD 84 million<\/strong> in its Series A round, adding to the <strong>USD 72 million<\/strong> raised last year to help bring its radiopharmaceuticals to market. The extension to the first round included <strong>Merck&#8217;s<\/strong> venture capital arm and other investors (<strong>BMS and Novartis<\/strong> were already on board), bringing the total raised by the Massachusetts biotech to <strong>USD 161 million<\/strong>. To deliver highly localized radiotherapy to tumors, <strong>Aktis&#8217; technology<\/strong> platform employs alpha radiation, which has limited penetrating power.<\/p>\n\n\n\n<p>The company&#8217;s drugs are designed to target receptors on tumor cells, delivering alpha particles deep within cancer or its metastases while also rapidly clearing from the body, reducing whole-body radiation exposure. The cell-killing potency of alpha particles is approximately <strong>1,000 times<\/strong> that of beta particle-emitting therapies, such as <strong>Novartis&#8217;<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/177-lutetium-psma-617-emerging-drug-insight-and-market-forecast\">Lutetium-177-based cancer therapies<\/a> <strong>Lutathera and Pluvicto<\/strong>, and older drugs based on radioactive iodine. According to <strong>Aktis<\/strong>, alpha particle therapies are also less likely to cause treatment resistance because they cause breaks in both strands of DNA in cancer cells.<\/p>\n\n\n\n<p>The Cambridge biotech&#8217;s pipeline consists of &#8216;mini protein&#8217; conjugate molecules linked to <strong>Actinium-225<\/strong>, an alpha-emitting isotope, focusing on breast, lung, bladder, liver, and colorectal cancer therapies. It negotiated supply agreements with <strong>NorthStar Medical, Niowave, and TerraPower<\/strong> earlier this month to provide radioisotopes for its programs. Along with <strong>Merck&#8217;s MRL Ventures Fund<\/strong>, <strong>Cowen Healthcare Investments, ArrowMark Partners, Mirae Asset Venture Investment, Timefolio Capital, and Pappas Capital <\/strong>participated in the Series A extension.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Koye_Pharma_Partners_with_Sonde_Health_to_Develop_its_Vocal_Biomarker_Technology_for_COPD\"><\/span><strong>Koye Pharma Partners with Sonde Health to Develop its Vocal Biomarker Technology for COPD<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Koye Pharma<\/strong>, an Indian pharmaceutical company, has partnered with <strong>Sonde Health<\/strong> to develop its vocal biomarker technology, which aims to diagnose diseases based on voice patterns, for use in <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\">chronic obstructive pulmonary disease (COPD)<\/a>. Koye, based in Mumbai, is the first pharmaceutical company to collaborate with <strong>Sonde Health<\/strong> on the technology, which is also used in a standalone app to monitor people&#8217;s mental health and well-being.<\/p>\n\n\n\n<p>The Indian company had already been developing its own vocal biomarker for respiratory diseases but will now combine it with Sonde Health&#8217;s technology to develop a new biomarker specifically for India&#8217;s <strong>50 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-epidemiology\">COPD patients<\/a>. <strong>Boston, Massachusetts Sonde Health<\/strong>, a PureTech Health company, has previously tested the technology as a diagnostic for respiratory diseases.<\/p>\n\n\n\n<p>Prior research has shown that a six-second voice sample can detect asthma and COPD symptoms and provide an early warning for <a href=\"https:\/\/www.delveinsight.com\/covid19\">COVID-19 infections<\/a>. Earlier this year, it collaborated with hearing aid specialist <strong>GN Group<\/strong> to develop vocal biomarker technology to detect mild cognitive impairment, which can be an early warning sign for diseases such as Alzheimer&#8217;s.<\/p>\n\n\n\n<p>Koye sells generic medicines, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-pipeline-insight\">COPD therapies<\/a> such as <strong>Spirodin (doxofylline) and Spirodin-Ax (doxofylline and ambroxol)<\/strong>, which are used to open the airways and reduce coughing in patients with the respiratory condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_Announces_Intention_to_Separate_Sandoz_to_Create_a_Standalone_Company\"><\/span><strong>Novartis Announces Intention to Separate Sandoz to Create a Standalone Company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Novartis <\/strong>announced its plans to separate <strong>Sandoz<\/strong>, its generics &amp; biosimilars division, into a new publicly traded standalone company, by way of a <strong>100 per cent spin-off<\/strong>.<\/p>\n\n\n\n<p>The spin-off aims to expand shareholder value by creating the #1 European generics company and a global leader in the filed of <a href=\"https:\/\/www.delveinsight.com\/report-store\/biosimilars-market\"><strong>biosimilars<\/strong><\/a> which allows Novartis shareholders to engage fully in the potential future upside for both, <strong>Novartis and Sandoz Innovative Medicines<\/strong>.<\/p>\n\n\n\n<p>For the Innovative Medicines and Sandoz businesses, the spin-off would be able enhance focus and the ability to pursue independent growth strategies. Sandoz is predicted to deliver its next wave of growth based on the existing biosimilar pipeline of <strong>15+ molecules<\/strong>, a solid &amp; experienced team, and organization. Novartis aspires to become a focused innovative medicines firm with a more robust financial profile &amp; improved capital return.<\/p>\n\n\n\n<p>The standalone Sandoz would be headquartered in Switzerland and will be listed on the <strong>SIX Swiss Exchange<\/strong>, with an <strong>American Depositary Receipt program<\/strong> in the <strong>United States<\/strong>.<\/p>\n\n\n\n<p>Our strategic review inspected all the options for Sandoz and concluded that a 100 per cent spin-off is the best option for shareholders. A spin-off would allow our shareholders to profit from the potential future accomplishments of a more focused Novartis and a standalone Sandoz, and would provide differentiated and clear investment theses for individual businesses. Sandoz will become the publicly traded <strong>#1 European generics company<\/strong> and a global leader in biosimilars based in Switzerland,\u201d added Joerg Reinhardt, Chair of the Board of Directors, Novartis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Alcon_to_Buy_Aerie_Pharma_for_About_USD_753_Million\"><\/span><strong>Alcon to Buy Aerie Pharma for About USD 753 Million<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The companies, <strong>Alcon <\/strong>and <strong>Aerie Pharmaceuticals <\/strong>have entered into a definitive merger agreement through which Alcon will acquire Aerie. This transaction confirms Alcon\u2019s commitment to the ophthalmic pharmaceutical space and is predicted to add broader pharmaceutical research and development capabilities to Alcon\u2019s existing commercial expertise, increasing the value of its diversified portfolio.<\/p>\n\n\n\n<p>Through this transaction, Alcon will add the commercial products <strong>Rocklatan 0.02 per cent\/0.005 per cent<\/strong> and <strong>Rhopressa 0.02 per cent<\/strong>, as well as <strong>AR-15512<\/strong>, a <strong>Phase III <\/strong>product candidate for <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-market-insights\"><strong>dry eye disease<\/strong><\/a>, and a pipeline assessment of various <strong>clinical <\/strong>and <strong>pre-clinical ophthalmic pharma product candidates<\/strong>. The transaction accompanies Alcon\u2019s recent expansion into the ophthalmic pharmaceutical eye drop space, including acquisitions of the exclusive United States commercialization rights to <strong>Simbrinza <\/strong>from <strong>Novartis <\/strong>in <strong>April&#8217;21 <\/strong>and of <strong>Eysuvis <\/strong>and <strong>Inveltys <\/strong>from <strong>Kala Pharmaceuticals <\/strong>in <strong>May&#8217;22<\/strong>.<\/p>\n\n\n\n<p><strong>Rocklatan <\/strong>is a <strong>fixed-dose combination<\/strong> of the <strong>netarsudil<\/strong>, <strong>Rho kinase inhibitor<\/strong>, and <strong>latanoprost (a prostaglandin F2\u03b1 analogue)<\/strong>, indicated for the reduction of elevated intraocular pressure in patients suffering with <a href=\"https:\/\/www.delveinsight.com\/report-store\/open-angle-glaucoma-market\"><strong>open-angle glaucoma<\/strong><\/a> or <a href=\"https:\/\/www.delveinsight.com\/report-store\/ocular-hypertension-market\"><strong>ocular hypertension<\/strong><\/a>. <strong>Rhopressa <\/strong>is a <strong>Rho kinase inhibitor<\/strong> for removing elevated intraocular pressure in patients suffering with <strong>open-angle glaucoma <\/strong>or <strong>ocular hypertension<\/strong>. In most markets outside the <strong>United States<\/strong>, commercialization rights for both products have been licensed to <strong>Santen SA <\/strong>and <strong>its affiliates<\/strong>.<\/p>\n\n\n\n<p>The purchase price of <strong>$15.25 per share<\/strong> serves a premium of<strong> 37 per cent<\/strong> to Aerie\u2019s last closing price and an equity value of approximately <strong>$770 million<\/strong>. The board approved the transaction of directors of each firm.<\/p>\n\n\n\n<p>Aerie\u2019s most recent financial guidance for total glaucoma franchise net product revenue is <strong>$130-140 million<\/strong> for <strong>2022<\/strong>. The transaction is expected to accrue to Alcon\u2019s core diluted Earnings Per Share in 2024. The transaction is expected to close in the fourth quarter of 2022.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Ibrutinib_for_Pediatric_Patients_With_Chronic_GVHD\"><\/span><strong>FDA Approves Ibrutinib for Pediatric Patients With Chronic GVHD<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Janssen Pharmaceutical has announced that the <strong>USFDA <\/strong>has approved its <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-pipeline-insight\"><strong>chronic graft-versus-host disease (cGVHD) therapy<\/strong><\/a>, IMBRUVICA\u00ae (ibrutinib), for the treatment in pediatric patients one year and older with after the failure of one or more lines of systemic therapy. With this approval, IMBRUVICA\u00ae became the first FDA-approved therapy for younger patients who previously had no approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-market\"><strong>treatment options in the cGVHD therapeutics market<\/strong><\/a>.&nbsp;<\/p>\n\n\n\n<p>IMBRUVICA\u00ae (ibrutinib) approval is based on the results from the Phase 1\/2 iMAGINE study, an open-label, multicenter, single-arm trial evaluating the potential of IMBRUVICA\u00ae for the treatment of pediatric and young adult patients aged one year to less than 22 years with <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-epidemiology-forecast\"><strong>moderate or severe cGVHD<\/strong><\/a>. Owing to its unique kinase profile (e.g., inhibiting both BTK and interleukin-2-inducible T-cell kinase [ITK]), IMBRUVICA\u00ae&nbsp; has the potential to provide a better <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-pipeline-insight\"><strong>clinical benefit for cGVHD<\/strong><\/a>.<\/p>\n\n\n\n<p>In 2013, The U.S. Food and Drug Administration (FDA) first approved IMBRUVICA\u00ae and as of today, it is in use for six diseases in adult patients, including five hematologic cancers. Earlier in 2017, IMBRUVICA\u00ae was approved to <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-market\"><strong>treat adults with cGVHD<\/strong><\/a> after failure of one or more lines of systemic therapy. The therapy is approved in over 100+ countries, and nearly 250,000 patients worldwide have been benefitted from it.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Grants_Fast_Track_Designation_to_Mercks_MK-2060_for_ESRD\"><\/span><strong>FDA Grants Fast Track Designation to Merck\u2019s MK-2060 for ESRD<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck has announced that the U.S. FDA has granted Fast Track designation to its investigational anticoagulant therapy MK-2060 to reduce the risk of major thrombotic cardiovascular events in <a href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-market\"><strong>patients with End-Stage Renal Disease (ESRD)<\/strong><\/a>. MK-2060 is an investigational monoclonal antibody currently being studied in the phase II stage in <a href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-epidemiology-forecast\"><strong>End-Stage Renal Disease (ESRD) patients<\/strong><\/a> receiving hemodialysis.&nbsp;<\/p>\n\n\n\n<p>MK-2060 is administered intravenously, and it works through a dual mechanism of action (MoA), blocking the activation of Factor XI and downstream activity of the activated protein. As per the estimates, the current Phase 2 clinical trial of MK-2060 is expected to be completed by April 2023. With the further approval and launch of the therapy MK-2060, Merck&#8217;s presence in the cardiovascular therapeutics segment is expected to strengthen.&nbsp;<\/p>\n\n\n\n<p>End-Stage Renal Disease (ESRD), also known as end-stage renal failure, is the final, permanent stage of chronic kidney disease in which kidney function has declined to the point that the kidneys no longer function on their own. In this condition, kidneys only function at 10\u201315% of their normal capacity, and the patient must receive dialysis or kidney transplantation to survive more than a few weeks.&nbsp; As per DelveInsight, in the United States, the overall <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-market\"><strong>prevalence of Chronic Kidney Disease (CKD)<\/strong><\/a> is around 14% of the general population.&nbsp;<\/p>\n\n\n\n<p>The therapy, MK-2060, is a novel inhibitor of Factor XI and has the ability to activate downstream proteins involved in the blood coagulation cascade and tends to <a href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-pipeline-insight\"><strong>prevent thrombosis in patients with End-Stage Renal Disease (ESRD)<\/strong><\/a>. The FDA\u2019s Fast Track Designation to MK-2060 will facilitate the Accelerated Approval and Priority Review if the findings from the clinical studies prove fruitful. The approval of the therapy is expected to play a key role in preventing thrombosis in patients with advanced forms of kidney disease.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"France_Regulator_Gives_The_Green_Light_to_Bayers_Asklepios_BioPharma_to_Start_Dosing_Patients_with_its_Gene_Therapy_Candidate\"><\/span><strong>France Regulator Gives The Green Light to Bayer\u2019s Asklepios BioPharma to Start Dosing Patients with its Gene Therapy Candidate<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Bayer\u2019s <strong>Asklepios BioPharma<\/strong>\u2019s (AskBio) BrainVectis has been approved by the France regulatory for the usage of their novel gene therapy candidate to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">Huntington\u2019s disease<\/a>, a neurogenerative disorder caused by a single defective gene on chromosome 4.&nbsp;<\/p>\n\n\n\n<p>The gene therapy candidate has been given a green light to start Phase I and Phase II clinical trials in which a single shot of <strong>BV-101<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\">gene therapy<\/a> will be administered using the vector adeno-associated virus (AAV) directly to the affected parts of the brain.&nbsp;<\/p>\n\n\n\n<p>The therapy delivers <strong>CYP46A1<\/strong>, an enzyme that is reduced in the brains of people with the disorder that is involved in cholesterol metabolism and seems to play a crucial role in the pathogenesis and progression of neurodegenerative disorders.&nbsp;<\/p>\n\n\n\n<p>During the initial phases of animal studies, it was observed that the therapy has shown to persist a neuroprotective effect along with which it aided in repairing a faulty cholesterol pathway and restoring physical function.&nbsp;<\/p>\n\n\n\n<p>As per the founder BrainVectis and vice president of neurobiology at AskBio Nathalie Cartier-Lacave, \u201cthe BV-101 aims towards restoring cholesterol metabolism, reducing the mutated Huntingtin genes, and improving neuronal functioning\u201d. The candidate has shown no direct effect on levels of the Huntingtin gene.&nbsp;<\/p>\n\n\n\n<p>Bayer cracked a <strong>USD 4 billion<\/strong> deal by acquiring US-based Biotech Asklepios BioPharmaceutical back in 2020 expressing his interest in gene therapy and biotechnology.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Takeda_Secures_its_First_Regulatory_Approval_in_Indonesia_for_its_Dengue_Fever_Vaccine_TAK-003\"><\/span><strong>Takeda Secures its First Regulatory Approval in Indonesia for its Dengue Fever Vaccine TAK-003<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Takeda\u2019s dengue vaccine, QDENGA\u00ae was recently approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM). The vaccine focuses on prophylaxis of<a href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-fever-pipeline-insight\"> dengue <\/a>caused by a number of serotypes in individuals aged between <strong>six to 45 years<\/strong>. It is to be noted that the usage of the vaccine is in accordance with the official recommendations. QDENGA stands to be one of the three vaccine candidates officially approved for use within the population.<\/p>\n\n\n\n<p>In the past few years, Indonesia has suffered half of the disease burden inside Southeast Asia i.e. the highest dengue burden in the world. During the initial half of 2020, the country reported around <strong>63K cases<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-pipeline-insight\">dengue<\/a> and accounted for around <strong>600 deaths<\/strong>.&nbsp;<\/p>\n\n\n\n<p>QDENGA successfully showed prophylaxis against dengue for more than three years regardless of the patient&#8217;s previous dengue records. Moreover, it did not show any serious risks that were previously seen in TIDES trials. The vaccine is genetically modified using a live-attenuated dengue serotype virus-2 which serves to be the genetic backbone of all four dengue subtypes. The vaccine is administered <strong>SC 0.5 mL dose<\/strong> at a two-dose on an interval of 3 months.&nbsp;More than <strong>28K participants<\/strong> were tested during the clinical trials of the candidate which included the participants of the TIDES trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals Aktis Oncology has raised an additional USD 84 million in its Series A round, adding to the USD 72 million raised last year to help bring its radiopharmaceuticals to market. The extension to the first round included Merck&#8217;s venture capital arm and other [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":18719,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17393,19680,3702,719,17444,718,10830,622,18957,19604,19681,19605,258,305,349,420,19207,19006,639,5789],"industry":[17225],"therapeutic_areas":[17242,17240,17238,17227,17231,17244,17234],"class_list":["post-18716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biosimilars","tag-chronic-graft-versus-host-disease","tag-chronic-kidney-disease","tag-chronic-obstructive-pulmonary-disease","tag-ckd","tag-copd","tag-covid-19","tag-dengue","tag-dry-eye-disease","tag-end-stage-renal-disease","tag-end-stage-renal-disease-esrd","tag-esrd","tag-gene-therapy","tag-huntingtons-disease","tag-latest-pharma-news","tag-news","tag-ocular-hypertension","tag-open-angle-glaucoma","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-ophthalmology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Aktis, Alcon, Takeda, Koye, Novartis, Merck, Janssen<\/title>\n<meta name=\"description\" content=\"Merck\u2019s MK-2060; Janssen&#039;s Ibrutinib; BrainVectis\u2019s CYP46A1; Takeda\u2019s TAK-003 Approval; Koye Partners with Sonde; Alcon to Buy Aerie Pharma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Aktis, Alcon, Takeda, Koye, Novartis, Merck, Janssen\" \/>\n<meta property=\"og:description\" content=\"Merck\u2019s MK-2060; Janssen&#039;s Ibrutinib; BrainVectis\u2019s CYP46A1; Takeda\u2019s TAK-003 Approval; Koye Partners with Sonde; Alcon to Buy Aerie Pharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-30T11:41:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-13T05:04:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/30171029\/Pharma-News-for-Aktis-Alcon-and-Takeda.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Aktis, Alcon, Takeda, Koye, Novartis, Merck, Janssen","description":"Merck\u2019s MK-2060; Janssen's Ibrutinib; BrainVectis\u2019s CYP46A1; Takeda\u2019s TAK-003 Approval; Koye Partners with Sonde; Alcon to Buy Aerie Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Aktis, Alcon, Takeda, Koye, Novartis, Merck, Janssen","og_description":"Merck\u2019s MK-2060; Janssen's Ibrutinib; BrainVectis\u2019s CYP46A1; Takeda\u2019s TAK-003 Approval; Koye Partners with Sonde; Alcon to Buy Aerie Pharma","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-08-30T11:41:15+00:00","article_modified_time":"2022-10-13T05:04:56+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/30171029\/Pharma-News-for-Aktis-Alcon-and-Takeda.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda","name":"Pharma News | Aktis, Alcon, Takeda, Koye, Novartis, Merck, Janssen","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/30171029\/Pharma-News-for-Aktis-Alcon-and-Takeda.png","datePublished":"2022-08-30T11:41:15+00:00","dateModified":"2022-10-13T05:04:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Merck\u2019s MK-2060; Janssen's Ibrutinib; BrainVectis\u2019s CYP46A1; Takeda\u2019s TAK-003 Approval; Koye Partners with Sonde; Alcon to Buy Aerie Pharma","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-aktis-alcon-takeda#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/30171029\/Pharma-News-for-Aktis-Alcon-and-Takeda.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/30171029\/Pharma-News-for-Aktis-Alcon-and-Takeda.png","width":772,"height":482,"caption":"Pharma News for Aktis, Alcon and Takeda"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/30171029\/Pharma-News-for-Aktis-Alcon-and-Takeda-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biosimilars<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic graft-versus-host disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Kidney Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CKD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COPD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">dengue<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dry Eye disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">End-Stage Renal Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">End-Stage Renal Disease (ESRD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ESRD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ocular Hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">open-angle glaucoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biosimilars<\/span>","<span class=\"advgb-post-tax-term\">chronic graft-versus-host disease<\/span>","<span class=\"advgb-post-tax-term\">Chronic Kidney Disease<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/span>","<span class=\"advgb-post-tax-term\">CKD<\/span>","<span class=\"advgb-post-tax-term\">COPD<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">dengue<\/span>","<span class=\"advgb-post-tax-term\">Dry Eye disease<\/span>","<span class=\"advgb-post-tax-term\">End-Stage Renal Disease<\/span>","<span class=\"advgb-post-tax-term\">End-Stage Renal Disease (ESRD)<\/span>","<span class=\"advgb-post-tax-term\">ESRD<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Ocular Hypertension<\/span>","<span class=\"advgb-post-tax-term\">open-angle glaucoma<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Aug 30, 2022","modified":"Updated on Oct 13, 2022"},"absolute_dates_time":{"created":"Posted on Aug 30, 2022 5:11 pm","modified":"Updated on Oct 13, 2022 10:34 am"},"featured_img_caption":"Pharma News for Aktis, Alcon and Takeda","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18716"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18716\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18719"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18716"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18716"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}